Response to Yang et. al.
Response to Yang et. al.
复制标题
对杨等人的回应
DOI：
10.1007/s00109-019-01775-z
复制
发表时间：
2019
期刊：
影响因子：
4.7
通讯作者：
Takeuchi T.
中科院分区：
文献类型：
--
作者：
Asano Y;Saigo C;Kito Y;Iwata Y;Yoshida K;Takeuchi T.
致编辑：我们感谢Yang及其同事对我们最近发表的题为B乳腺癌发生中LDL受体相关蛋白1B的核定位^[1]的文章提出的建设性意见。正如Yang等人感兴趣地指出的那样，核定位的LDL受体相关蛋白1B（LRP 1B）可能是乳腺癌患者的新治疗靶点。我们想特别强调的是，LRP 1B细胞内结构域的核定位与管腔A型乳腺癌患者的淋巴结转移和不良预后显著相关（其倾向于雌激素和孕激素受体阳性而HER-2阴性）。然而，并非所有晚期雌激素受体阳性乳腺癌患者都能从内分泌治疗中获益。不幸的是，有时会遇到治疗困难，包括最小的初始反应，更常见的是，在对内分泌治疗的初始反应之后，进展期间几乎没有反应[2]。目前的发现表明，废除LRP 1B的胞内结构域的核输入可能会使许多对内分泌治疗产生新发耐药的管腔A型乳腺癌患者受益。在这项研究中，正如Yang及其同事所指出的，我们首次确定了LRP 1B的胞内结构域的核分数与乳腺癌发生患者的不良预后显著相关。此后，我们应用基于微阵列的分析来筛选在模拟转染的MCF-7细胞和对照组之间差异表达的基因。
To the editor: We would like to express our appreciation to Yang and colleagues for their constructive comments on our recent article entitled BNuclear localization of LDL receptorrelated protein 1B in mammary gland carcinogenesis^[1]. As Yang et al. have noted with interest, nuclearlocalized LDL receptor-related protein 1B (LRP1B) may be a new therapeutic target for patients with breast cancer. We would like to especially emphasize that nuclear localization of the LRP1B intracellular domain was significantly correlated with lymph node metastasis and poor prognosis of patients with luminal A-type breast cancers (which tend to be positive for estrogen and progesterone receptors and negative for HER-2). However, not all patients with advanced estrogen receptor positive breast cancer benefit from endocrine therapy. Unfortunately, treatment difficulties are sometimes encountered including minimal initial response, and more commonly, little response during progression, following an initial response to endocrine therapy [2]. The present finding indicates that abrogating nuclear import of the intracellular domain of LRP1B may benefit many patients with luminal A-type breast cancer who present de novo resistance to endocrine therapy.In this study, as pointed out by Yang and colleagues, we first identified the nuclear fraction of the intracellular domain of LRP1B as having a significant correlation with poor prognosis in mammary gland carcinogenesis patients. Thereafter, we applied a microarray-based assay to screen for genes that are differentially expressed between mock transfected MCF-7